FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.-论文-万方医学网

第一作者： F,Loupakis

第一单位： Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy. Electronic address: fotiosloupakis@gmail.com.

作者： F,Loupakis ^[1] ; C,Cremolini ^[2] ; L,Salvatore ^[2] ; G,Masi ^[2] ; E,Sensi ^[3] ; M,Schirripa ^[2] ; A,Michelucci ^[4] ; E,Pfanner ^[2] ; I,Brunetti ^[5] ; C,Lupi ^[3] ; C,Antoniotti ^[2] ; F,Bergamo ^[6] ; S,Lonardi ^[6] ; V,Zagonel ^[6] ; P,Simi ^[4] ; G,Fontanini ^[3] ; A,Falcone ^[7]

作者单位： Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy. Electronic address: fotiosloupakis@gmail.com. ^[1] Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy. ^[2] Division of Pathology, Department of Surgery, University of Pisa, Via Roma 67, 56126 Pisa, Italy. ^[3] Unit of Medical Genetics, Azienda Ospedaliera-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy. ^[4] Unit of Medical Oncology 1, Azienda Ospedaliera-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy. ^[5] Unit of Medical Oncology 1, Oncology Institute of Veneto, Via Gattamelata 64, 35138 Padua, Italy. ^[6] Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy; Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Via Roma 67, 56126 Pisa, Italy. ^[7]

医学主题词成年人(Adult);老年人(Aged);血管生成抑制剂(Angiogenesis Inhibitors);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);喜树碱(Camptothecin);结直肠肿瘤(Colorectal Neoplasms);无病生存(Disease-Free Survival);女(雌)性(Female);氟尿嘧啶(Fluorouracil);人类(Humans);醛氢叶酸(Leucovorin);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);肿瘤转移(Neoplasm Metastasis);有机铂化合物(Organoplatinum Compounds);预后(Prognosis);前瞻性研究(Prospective Studies);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);回顾性研究(Retrospective Studies);存活率(Survival Rate);治疗结果(Treatment Outcome)

DOI 10.1016/j.ejca.2013.08.024

PMID 24138831

发布时间 2022-03-31

检索历史清除

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.

European journal of cancer (Oxford, England

相似文献

同项目论文

European journal of cancer (Oxford, England

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.

European journal of cancer (Oxford, England

相似文献

同项目论文

European journal of cancer (Oxford, England

相关期刊

检索历史清除